Getting To The Heart Of The 40-Year-Long Framingham Study

In 1948, a group of government researchers arrived in a small New England city to begin a long-term epidemiologic study of its residents. In the ensuing 42 years, their research has come to have considerable impact on health care in the United States. The project, the Framingham Heart Study, conducted by the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health, has provided surveillance of the cardiac health of a randomly selected sample of men and women from

Written byLisa Holland
| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

The project, the Framingham Heart Study, conducted by the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health, has provided surveillance of the cardiac health of a randomly selected sample of men and women from Framingham, Mass. (see accompanying story). Its prospective nature has made it possible to define factors that may eventually lead to cardiovascular disease and, as a result, has triggered national health trends geared to intervene and reduce risk.

As the data-collecting phase of the study draws to a close (funding is expected to expire in 1992), a look back over the past several decades reveals a body of valuable information that has had significant impact in cardiovascular disease research.

"The Framingham Heart Study was created to study the incidence of coronary heart disease and the factors related to its development," explains William B. Kannel, former study director and currently professor of medicine ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies